Document Type : Original Article
Authors
- Abdorreza Naser Moghadasi 1
- Saeed Vaheb 2
- Sara Hamtaei-Ghashti 3
- Aysa Shaygannejad 2
- Mozhdeh Askari 2
- Vahid Shaygannejad 2
- Mohmmad Ali Sahraian 3
- Mahsa Ghajarzadeh 4
1 Department of Neurology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
2 Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3 Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
4 Brain and Spinal Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Background: Fear of relapse and re-infection during the coronavirus disease 2019 (COVID-19) pandemic can affect people with chronic relapsing diseases, such as multiple sclerosis (MS). We evaluated fear of re-infection, anxiety, and relapse during the COVID-19 pandemic in Iranian people with MS.
Methods: This multicenter, cross-sectional study was performed in the MS clinic of Sina Hospital, Tehran, Iran, and Hakim Private Hospital, Isfahan, Iran, between January and April 2022. We asked the participants to fill out validated Persian versions of Fear of Relapse Scale (FoR), and Beck Anxiety Inventory (BAI) questionnaires and answer a binary question about their fear of getting reinfected with COVID-19. Results were reported as mean ± standard deviation (SD) for continuous variables or frequencies for categorical variables. For continuous variables which did not have a normal distribution, we reported the median and interquartile range (IQR). Spearman correlation coefficient between anxiety score and FoR score was calculated. An independent samples t-test was used to compare continuous variables.
Results: Three hundred and sixty-eight patients participated in this study. The median scores of FoR and BAI were 49.7 and 34.3, respectively. Fifty-three had new relapses in their last infection. Thirty-six percent of the patients had a fear of getting COVID-19 again, and 43% had a fear of relapse
during infection. Three hundred and twenty-three had two doses of COVID-19 vaccine; the most frequent type of vaccine was Sinopharm. There was a significant difference between the median FoR scores among patients with and without relapse during the last COVID-19. There was also a significant positive correlation between anxiety score and FoR (r = 0.49, P < 0.001).
Conclusion: More than one-third of enrolled cases had fear of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) re-infection. Patients who experienced exacerbation of symptoms even in the form of relapse or pseudo relapse (possible clinical relapse) had a higher fear of infection.
Keywords
- Mirmosayyeb O, Shaygannejad V, Nehzat N, Mohammadi A, Ghajarzadeh M. Prevalence of seizure/epilepsy in patients with multiple sclerosis: a systematic review and meta-analysis. Int J Prev Med 2021; 12: 14.
- Halper J. The psychosocial effect of multiple sclerosis: The impact of relapses. J Neurol Sci 2007; 256(Suppl 1): S34-S38.
- Ghajarzadeh M, Azizi S, Moghadasi AN, Sahraian MA, Azimi A, Mohammadifar M, et al. Validity and reliability of the Persian Version of the PERception de la Scle'rose En Plaques et de ses Pousse'es Questionnaire Evaluating Multiple Sclerosis-related Quality of Life. Int J Prev Med 2016; 7: 25.
- Ghajarzadeh M, Bonavita S. Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection? Neurol Sci 2020; 41(9): 2315-6.
- Moghadasi AN, Mirmosayyeb O, Barzegar M, Sahraian MA, Ghajarzadeh M. The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): A systematic review and meta-analysis. Neurol Sci 2021; 42(8): 3093-9.
- Barzegar M, Mirmosayyeb O, Ghajarzadeh M, Nehzat N, Vaheb S, Shaygannejad V, et al. Characteristics of COVID-19 disease in multiple sclerosis patients. Mult Scler Relat Disord 2020; 45: 102276.
- Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord 2020; 43: 102195.
- Sahraian MA, Azimi A, Navardi S, Ala S, Naser MA. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord 2020; 46: 102472.
- Khatibi A, Moradi N, Rahbari N, Salehi T, Dehghani M. Development and validation of Fear of Relapse Scale for Relapsing-Remitting Multiple Sclerosis: Understanding stressors in patients. Front Psychiatry 2020; 11: 226.
- Shaygannejad V, Mirmosayyeb O, Nehzat N, Ghajarzadeh M. Fear of relapse, social support, and psychological well-being (depression, anxiety, and stress level) of patients with multiple sclerosis (MS) during the COVID-19 pandemic stage. Neurol Sci 2021; 42(7): 2615-8.
- Ramezani N, Ashtari F, Bastami EA, Ghaderi K, Hosseini SM, Naeini MK, et al. Fear and anxiety in patients with multiple sclerosis during COVID-19 pandemic; report of an Iranian population. Mult Scler Relat Disord 2021; 50: 102798.
- Rezaeimanesh N, Sahraian MA, Naser MA. Evaluation of the opinion of patients with multiple sclerosis on the outcomes of catching COVID-19 and its effects on the MS symptoms. Basic Clin Neurosci 2020; 11(2): 201-6.
- Michelena G, Casas M, Eizaguirre MB, Pita MC, Cohen L, Alonso R, et al. Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis. Mult Scler Relat Disord 2022; 57: 103368.
- Yazdani A, Mirmosayyeb O, Ghaffary EM, Hashemi MS, Ghajarzadeh M. COVID-19 vaccines and patients with multiple sclerosis: willingness, unwillingness and hesitancy: A systematic review and meta-analysis. Neurol Sci 2022; 43(7): 4085-94.
- Riva A, Barcella V, Benatti SV, Capobianco M, Capra R, Cinque P, et al. Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. Mult Scler 2021; 27(3): 347-59.
- Reyes S, Ramsay M, Ladhani S, Amirthalingam G, Singh N, Cores C, et al. Protecting people with multiple sclerosis through vaccination. Pract Neurol 2020; 20(6): 435-45.
- Ghadiri F, Sahraian MA, Azimi A, Moghadasi AN. The study of COVID-19 infection following vaccination in patients with multiple sclerosis. Mult Scler Relat Disord 2022; 57: 103363.
- Ozakbas S, Cagiran I, Ormeci B, Idiman E. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis. J Neurol Sci 2004; 218(1-2): 3-7.
)